JPM25: Bayer gears up for 'must-win battles' as Xarelto's decline is in full swing, pharma chief says

Although Bayer’s top-selling drug Xarelto lost market exclusivity in most geographies in 2024, the company still predicts it will see strong growth from the pharma business unit beginning in 2027.